Empagliflozin for Patients With Presumed Resistant Hypertension: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial.

Outcome events In both placebo- and empagliflozin-treated patients, patients with prHT were generally at increased risk for all outcomes compared with patients with no-prHT—with the only exception of all-cause mortality in the placebo group which only showed a weak trend in this respect (heart rate 1.13, 95% confidence interval, 0.82–1.56 for prHT vs. no-prHT).

also in 1,404 other papers